![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
48 Week Efficacy, Pharmacokinetics, and Safety of Once a Day 400 mg Nevirapine (Viramune) Extended Release Formulation for Treatment of Antiretroviral Naïve HIV-1 Infected Patients
|
|
|
Reported by Jules Levin
ICAAC Sept 14 2010 Boston
J. GATHE*, G. KNECHT, C. ORRELL, J. MALLOLAS, D. PODZAMCZER, B. TROTTIER, J. MORALES, T. NGUYEN, C. YONG, W. ZHANG, M. DRULAK and A. QUINSON
LIPIDS - Vienna: Comparison of 48 week efficacy and safety of 400mg QD nevirapine (NVP) extended release formulation (Viramune XR) versus 200mg BID nevirapine immediate release formulation (Viramune IR) in combination with emtricitabine/tenofovir in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE) - (07/22/10)
![](../images/091610/091610-11/image002.gif)
![](../images/091610/091610-11/image004.gif)
1. Gazzard et al. HIV Med 2008; 9:563-608
2. EACS Guidelines 2009 http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_Infected_Adults.pdf
3. DHHS 2009 http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf
4.Thompson A et al. JAMA 2010; 304:321-333
![](../images/091610/091610-11/image006.gif)
![](../images/091610/091610-11/image008.gif)
![](../images/091610/091610-11/image010.gif)
![](../images/091610/091610-11/image012.gif)
![](../images/091610/091610-11/image014.gif)
![](../images/091610/091610-11/image016.gif)
![](../images/091610/091610-11/image018.gif)
![](../images/091610/091610-11/image020.gif)
TS = Treated set
FAS = Full analysis set
![](../images/091610/091610-11/image022.gif)
![](../images/091610/091610-11/image024.gif)
![](../images/091610/091610-11/image026.gif)
*Includes pyrexia, laboratory abnormalities, nausea, headache, infections/infestations
TS = Treated set; FAS = Full analysis set
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|